Search results
Sun Pharma Prevails in Lipitor MDL on Class Certification, Summary Judgment | New Jersey Law Journal
Law.com· 6 days agoA group of Lipitor purchasers that included retailers, wholesalers, health insurance companies, and...
Pfizer study finds Paxlovid ineffective against Long COVID despite federal research funds
22 WSBT South Bend· 5 days agoLong COVID is a chronic condition resulting from an initial infective with COVID-19, according to...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 3 days agoThis week, an FDA advisory committee unanimously recommended approval of Eli Lilly’s LLY Alzheimer's...
Breakingviews: Hyundai’s India IPO will have imitators
Reuters· 22 minutes ago, opens new tab up to $3 billion initial public offering of its Indian business crystallises a...
Former Pfizer Worker’s 401(k) Account Won’t Be Given to Ex-Wife
Bloomberg Law· 3 days agoemployee can’t access his 401(k) account to satisfy a $75,000 judgment against him in a defamation lawsuit, a Pennsylvania federal judge said. Judge Juan R. Sánchez rejected her request with ...
COVID Variant KP.3 Surges to Dominance—Here's What You Need to Know
Health via Yahoo News· 4 days agoDo Vaccines Protect Against KP.3? Per Zambrano, all three COVID vaccine manufacturers—Pfizer,...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 4 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical company said Wednesday the ...
Here's To Science! Pfizer, Moderna Look To Combo Flu/COVID Vaccines
MediaPost· 6 days agoAlbert Bourla, Pfizer’s chief executive officer, acknowledged on Monday that, because the company’s stock price was down at the time, he gave the final sign-off on running ...
New COVID Mystery? Those 'Excess Deaths'
newser· 9 hours agoWith hospitals swamped at the same time, excess deaths spiked considerably from causes including heart disease, stroke, and diabetes. COVID vaccines...
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory...
Morningstar· 3 days agoPfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily ...